Related Experiment Video
Updated: Jun 5, 2026
12:28
Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains
Published on: June 3, 2020
Lobar atrophy in frontotemporal dementia: diagnostic and prognostic implications
1The Walton Centre for Neurology and Neurosurgery, Liverpool, UK. rhys.davies@thewaltoncentre.nhs.uk
Current Alzheimer Research
|January 13, 2011
Summary
Frontotemporal dementia (FTD) diagnosis and prognosis rely on identifying lobar atrophy patterns. Caution is advised when diagnosing FTD without visible brain atrophy, especially in behavioral presentations.
Area of Science:
- Neurology
- Neuroimaging
- Cognitive Neuroscience
Background:
- Frontotemporal dementia (FTD) presents diagnostic challenges, particularly behavioral variants.
- Interpreting MRI scans in FTD cases, especially those without clear aphasic or motor impairments, can be difficult.
- The FTD phenocopy concept complicates clinical diagnosis.
Purpose of the Study:
- To review the diagnostic and prognostic significance of lobar atrophy in FTD.
- To explore patterns of frontotemporal atrophy associated with FTD subtypes.
- To emphasize the importance of MRI findings in diagnosing behavioral FTD.
Main Methods:
- Review of clinical and pathological literature on FTD.
- Analysis of MRI findings in relation to FTD subtypes and progression.
- Discussion of the FTD phenocopy concept and its diagnostic implications.
Main Results:
- Specific patterns of lobar atrophy correlate with distinct clinical and pathological FTD subtypes, such as semantic dementia.
- Lobar atrophy is a crucial indicator for identifying behavioral FTD patients with likely disease progression.
- Interpreting MRI scans in FTD can be challenging, especially for behavioral presentations.
Conclusions:
- Lobar atrophy is a key factor in the diagnosis and prognosis of FTD.
- Visible brain atrophy on MRI is important for confirming FTD diagnoses, particularly in behavioral cases.
- Clinical caution is necessary when diagnosing FTD without evidence of brain atrophy.
Related Concept Videos
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...